Serum Institute, Bharat Biotech pledge smooth roll out of COVID-19 vaccines
Adar Poonawalla, Chief Executive Officer of Serum Institute of India, and Krishna Ella, Chairman and Managing Director of Bharat Biotech, jointly on behalf of the two companies, communicated their combined intent to develop manufacture and supply the COVID-19 vaccines for India and globally.
They said, the more important task in front of them is saving the lives and livelihoods of populations in India and the world. Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest.
“Now that two COVID-19 vaccines have been issued EUA (emergency use authorization) in India, the focus is on manufacturing, supply and distribution, such that populations that need it the most receive high quality, safe and efficacious vaccines. Both our Companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines. Each of our Companies continue their COVID-19 vaccines development activities as planned,” the joint statement said.